Background: Psoriasis is a chronic inflammatory disorder with proliferative dermatological and systemic manifestations involving multiple organs. Its etiology and pathogenesis is closely related with genetic and environmental factors. The current study was designed to assess the relationship of age at the diagnosis of psoriasis and its impact on their quality of life. The findings thus obtained might help to take appropriate therapeutic and psychological measures together with patients’ counselling to minimize any adverse consequences. Aim: To determine the age of diagnosis of psoriasis and its impact on the quality of life with age quartiles in psoriasis patients. Setting: This cross sectional study was carried out in Dermatology out patients department (OPD) affiliated with Liaquat University Hospital (LUH), Hyderabad from December 2019 to June 2020. Methodology: Total 141 diagnosed cases of psoriasis vulgaris were included in the study. The final data in the form of DLQI SCORE, PASI SCORE in each quartile of age of all patients was collected and findings were noted down in the predesigned proforma. Results: The average age of the patients included in the study was 37.53±12.12 years. There were 103 (73%) males and 38 females (27%) who consented to be the part of the study. Quality of life among 17 (12.06%) patients had little impact, 42 (29.79%) had moderate effect, 77 (54.61%) patients had severe effect and 5 (3.55%) had extreme effect. There is significant effect with respect to age quartiles at diagnosis of psoriasis (p=0.005). Significant effect on quality of life was observed in 1st and 2nd quartile while moderate effect appeared to impact the patients in 3rd quartile of age. Conclusion: Psoriasis is more than just a skin disorder and has a very large effect on patients’ quality of life with noticeable effects having potential to impact their personalities, daily routine activities and even relationships with people around them. Depending upon the severity of the disorder, it could affect quality of life without any discrimination of age, gender, duration and married life of patients. The more it is on the exposed parts, the more it affects their quality of life. Keywords: Psoriasis, Quality of life, DLQI score, PASI score.
Background: Warts are the hard, hyperkeratotic benign growths over the skin caused by human papilloma virus. It is one of the common skin conditions presented to the outpatient department. Various treatment options are available with variable success but sometimes it is resistant to treatment due to its depth in the dermis and relapsing nature. Aim: To compare clinical efficacy of 0.1% intralesional bleomycin solution and 0.05% intralesionalbleomycin solution in the patients with warts. Study settings & design: Experimental, Dermatology, LUMHS Jamshoro Duration: 1st January 2018 to 30th June 2018 Methods: 90 patients with persistent common warts were enrolled. Patients were examined and number of warts located on right and left hand, feet and leg of each patient were categorized in two groups as right sided group and left sided group respectively. The two concentrations of bleomycin were randomly adminitered to either right sided and left sided warts which are called, the lesion A in which 0.1% IL bleomycin solution was injected and the lesion B in which 0.05% IL bleomycin solution was injected respectively. The Response of the both therapies was assessed by measuring the size of warty lesions on 6thweek. Then patient was advised to report at the end of 14th week to observe any recurrence in the treated lesions and to assess the final clinical efficacy. Results: - Mean age of patients was 25.36 ± 6.09 years. There were 50(55.56%) male and 40(44.44%) females. Clinical efficacy as per operational definition i.e. Complete disappeared or >50% regression in size of warts with no recurrence was significantly high in lesion A than lesion B [93.3% vs. 68.9%; p=0.0005]. Regarding number of warts in patients, 86.1% of the warts were cured in lesion A while 64.9% were cure in lesion B. The difference was statistically significant. Conclusion: - Our results support that 0.1% IL Bleomycin is more effective in the treatment of viral warts as compared to 0.05% bleomycin. Keywords: Common Warts, Intralesional, Bleomycin treatment
This was a prospective cross-sectional study conducted to evaluate association of waist, hip and thigh circumferences on respiratory parameters among young healthy adults. A total of 180 volunteers of different weight categories; including underweight, normal weight, over weight and obese people were recruited by using non-probability convenient sampling technique. Non-smoker males and females (non-pregnant), aged between 18-40 years with no pulmonary and cardiac disease were included in the study. Waist circumference, mid-thigh circumference, hip circumference and respiratory parameters were measured. The results showed a significant association between waist circumference with forced vital capacity (FVC) (r = 0.188, p = 0.011), average tidal volume (VT) (r = 0.160, p = 0.032), inspiratory reserve volume (IRV) (r = 0.388,p<0.001), vital capacity (VC) (r = 0.312, p<0.001), total lung capacity (TLC) (r = 0.385, p<0.001), and functional residual capacity (FRC) (r = 0.477, p<0.01), and a negative association with forced expiratory volume in 1 second (FEV1) (r = -0.148, p = 0.048) and FEV1/FVC ratio (r = -0.246, p<0.001). Significant association was not observed between waist circumference and expiratory reserve volume (ERV) (r = 0.071, p = 0.344). In the present study, increased waist, hip, and thigh circumferences were found to be negatively associated with FEV1 and FEV1/FVC ratio. Spirometry should be performed in obese and overweight young healthy adults even if they are asymptomatic, as early preventive measures can be taken to reduce the resulting morbidity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.